Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Gains from Sales and Divestitures: 2019-2020

Historic Gains from Sales and Divestitures for Silence Therapeutics (SLN) over the last 2 years, with Dec 2020 value amounting to -$3,852.

  • Silence Therapeutics' Gains from Sales and Divestitures was N/A to $96,443 in Q2 2021 from the same period last year, while for Jun 2021 it was $96,443, marking a year-over-year change of. This contributed to the annual value of -$3,852 for FY2020, which is 250.86% down from last year.
  • Per Silence Therapeutics' latest filing, its Gains from Sales and Divestitures stood at -$3,852 for FY2020, which was down 250.86% from $2,554 recorded in FY2019.
  • Over the past 5 years, Silence Therapeutics' Gains from Sales and Divestitures peaked at $2,554 during FY2019, and registered a low of -$3,852 during FY2020.
  • For the 2-year period, Silence Therapeutics' Gains from Sales and Divestitures averaged around -$649.38, with its median value being -$649.38 (2019).
  • Data for Silence Therapeutics' Gains from Sales and Divestitures shows a maximum YoY slumped of 250.86% (in 2020) over the last 5 years.
  • Yearly analysis of 2 years shows Silence Therapeutics' Gains from Sales and Divestitures stood at $2,554 in 2019, then plummeted by 250.86% to -$3,852 in 2020.